{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:03:47Z","timestamp":1788609827043,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273484"],"award-info":[{"award-number":["82273484"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"project of Chongqing young and middle-aged medical talents"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Oncol."],"DOI":"10.1007\/s13402-026-01196-4","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T08:54:21Z","timestamp":1774256061000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A habitat radiomics model based on contrast-enhanced MRI for predicting early treatment response to hepatic arterial infusion chemotherapy in patients with unresectable hepatocellular carcinoma"],"prefix":"10.1007","volume":"49","author":[{"given":"Guanhui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhexuan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shujie","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangzhi","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"issue":"1","key":"1196_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"J.M. Llovet, R.K. Kelley, A. Villanueva, A.G. Singal, E. Pikarsky, S. Roayaie, R. Lencioni, K. Koike, J. Zucman-Rossi, R.S. Finn, Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 7(1), 6 (2021)","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"Pt 3","key":"1196_CR2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.semcancer.2021.07.017","volume":"86","author":"GP Nagaraju","year":"2022","unstructured":"G.P. Nagaraju, B. Dariya, P. Kasa, S. Peela, B.F. El-Rayes, Epigenetics in hepatocellular carcinoma. Semin Cancer Biol. 86(Pt 3), 622\u2013632 (2022)","journal-title":"Semin Cancer Biol."},{"issue":"1","key":"1196_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","volume":"23","author":"YT Chan","year":"2024","unstructured":"Y.T. Chan, C. Zhang, J. Wu, P. Lu, L. Xu, H. Yuan, Y. Feng, Z.S. Chen, N. Wang, Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol. Cancer. 23(1), 189 (2024)","journal-title":"Mol. Cancer"},{"issue":"10127","key":"1196_CR4","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"A. Forner, M. Reig, J. Bruix, Hepatocellular carcinoma. Lancet. 391(10127), 1301\u20131314 (2018)","journal-title":"Lancet"},{"issue":"3","key":"1196_CR5","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"F. Bray, M. Laversanne, H. Sung, J. Ferlay, R.L. Siegel, I. Soerjomataram, A. Jemal, Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J. Clin. 74(3), 229\u2013263 (2024)","journal-title":"Cancer J. Clin."},{"issue":"3","key":"1196_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/s-0044-1788691","volume":"8","author":"Y Zhang","year":"2024","unstructured":"Y. Zhang, Y. Wang, J.-H. Guo, J. Lu, Current Trends in Hepatocellular Carcinoma Therapies in China. Dig. Disease Interventions. 8(3), 173\u2013182 (2024)","journal-title":"Dig. Disease Interventions"},{"issue":"5","key":"1196_CR7","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1093\/jcag\/gwae025","volume":"7","author":"F Jaber","year":"2024","unstructured":"F. Jaber, G. Cholankeril, H.B. El-Serag, Contemporary epidemiology of hepatocellular carcinoma: understanding risk factors and surveillance strategies. J. Can. Association Gastroenterol. 7(5), 331\u2013345 (2024)","journal-title":"J. Can. Association Gastroenterol."},{"issue":"1","key":"1196_CR8","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41392-024-02075-w","volume":"10","author":"J Zheng","year":"2025","unstructured":"J. Zheng, S. Wang, L. Xia, Z. Sun, K.M. Chan, R. Bernards, W. Qin, J. Chen, Q. Xia, H. Jin, Hepatocellular carcinoma: signaling pathways and therapeutic advances. Signal. Transduct. Target. Ther. 10(1), 35 (2025)","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"2","key":"1196_CR9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/hep.27745","volume":"62","author":"S Roayaie","year":"2015","unstructured":"S. Roayaie, G. Jibara, P. Tabrizian, J.W. Park, J. Yang, L. Yan, M. Schwartz, G. Han, F. Izzo, M. Chen et al., The role of hepatic resection in the treatment of hepatocellular cancer. Hepatol. (Baltimore Md). 62(2), 440\u2013451 (2015)","journal-title":"Hepatol. (Baltimore Md)"},{"issue":"4","key":"1196_CR10","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/hep.23485","volume":"51","author":"G Cabibbo","year":"2010","unstructured":"G. Cabibbo, M. Enea, M. Attanasio, J. Bruix, A. Crax\u00ec, C. Camm\u00e0, A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatol. (Baltimore Md). 51(4), 1274\u20131283 (2010)","journal-title":"Hepatol. (Baltimore Md)"},{"issue":"Suppl 4","key":"1196_CR11","doi-asserted-by":"publisher","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","volume":"29","author":"A Vogel","year":"2018","unstructured":"A. Vogel, A. Cervantes, I. Chau, B. Daniele, J.M. Llovet, T. Meyer, J.C. Nault, U. Neumann, J. Ricke, B. Sangro et al., Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals oncology: official J. Eur. Soc. Med. Oncol. 29(Suppl 4), iv238\u2013iv255 (2018)","journal-title":"Annals oncology: official J. Eur. Soc. Med. Oncol."},{"key":"1196_CR12","doi-asserted-by":"crossref","unstructured":"W. Zhang, S. Tong, B. Hu, T. Wan, H. Tang, F. Zhao, T. Jiao, J. Li, Z. Zhang, J. Cai et al., Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial. J. Immunother. Cancer 2023, 11(9)","DOI":"10.1136\/jitc-2023-007366"},{"issue":"3","key":"1196_CR13","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s00280-018-3638-0","volume":"82","author":"JH Choi","year":"2018","unstructured":"J.H. Choi, W.J. Chung, S.H. Bae, D.S. Song, M.J. Song, Y.S. Kim, H.J. Yim, Y.K. Jung, S.J. Suh, J.Y. Park et al., Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Cancer Chemother. Pharmacol. 82(3), 469\u2013478 (2018)","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"1196_CR14","doi-asserted-by":"publisher","first-page":"39494","DOI":"10.1038\/s41598-025-23027-6","volume":"15","author":"M Jiang","year":"2025","unstructured":"M. Jiang, C. Chen, Y. Hu, G. Lin, H. Li, Locoregional therapy combined with targeted therapy and immunotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis. Sci. Rep. 15(1), 39494 (2025)","journal-title":"Sci. Rep."},{"issue":"2","key":"1196_CR15","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1200\/JCO.21.00608","volume":"40","author":"QJ Li","year":"2022","unstructured":"Q.J. Li, M.K. He, H.W. Chen, W.Q. Fang, Y.M. Zhou, L. Xu, W. Wei, Y.J. Zhang, Y. Guo, R.P. Guo et al., Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial. J. Clin. oncology: official J. Am. Soc. Clin. Oncol. 40(2), 150\u2013160 (2022)","journal-title":"J. Clin. oncology: official J. Am. Soc. Clin. Oncol."},{"issue":"7","key":"1196_CR16","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1001\/jamaoncol.2019.0250","volume":"5","author":"M He","year":"2019","unstructured":"M. He, Q. Li, R. Zou, J. Shen, W. Fang, G. Tan, Y. Zhou, X. Wu, L. Xu, W. Wei et al., Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial. JAMA Oncol. 5(7), 953\u2013960 (2019)","journal-title":"JAMA Oncol."},{"issue":"3","key":"1196_CR17","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3350\/cmh.2022.0391","volume":"29","author":"H Iwamoto","year":"2023","unstructured":"H. Iwamoto, S. Shimose, T. Shirono, T. Niizeki, T. Kawaguchi, Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity. Clin. Mol. Hepatol. 29(3), 593\u2013604 (2023)","journal-title":"Clin. Mol. Hepatol."},{"issue":"1","key":"1196_CR18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/s41392-023-01663-6","volume":"8","author":"TQ Zhang","year":"2023","unstructured":"T.Q. Zhang, Z.J. Geng, M.X. Zuo, J.B. Li, J.H. Huang, Z.L. Huang, P.H. Wu, Y.K. Gu, Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study. Signal. Transduct. Target. Ther. 8(1), 413 (2023)","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"5","key":"1196_CR19","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1097\/JS9.0000000000000256","volume":"109","author":"Y Yuan","year":"2023","unstructured":"Y. Yuan, W. He, Z. Yang, J. Qiu, Z. Huang, Y. Shi, Z. Lin, Y. Zheng, M. Chen, W.Y. Lau et al., TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study. Int. J. Surg. (London England). 109(5), 1222\u20131230 (2023)","journal-title":"Int. J. Surg. (London England)"},{"issue":"1","key":"1196_CR20","doi-asserted-by":"publisher","first-page":"21184","DOI":"10.1038\/s41598-025-08170-4","volume":"15","author":"C Zhang","year":"2025","unstructured":"C. Zhang, Y. Xu, L. Cai, S. Zhou, J. Feng, S. Fu, W. Wang, W. Liang, C. Li, W. Guo et al., Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study. Sci. Rep. 15(1), 21184 (2025)","journal-title":"Sci. Rep."},{"issue":"1","key":"1196_CR21","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jhep.2018.02.008","volume":"69","author":"N Lyu","year":"2018","unstructured":"N. Lyu, Y. Kong, L. Mu, Y. Lin, J. Li, Y. Liu, Z. Zhang, L. Zheng, H. Deng, S. Li et al., Hepatic arterial infusion of oxaliplatin plus fluorouracil\/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J. Hepatol. 69(1), 60\u201369 (2018)","journal-title":"J. Hepatol."},{"issue":"1","key":"1196_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2015.06.019","volume":"367","author":"J Chen","year":"2015","unstructured":"J. Chen, R. Jin, J. Zhao, J. Liu, H. Ying, H. Yan, S. Zhou, Y. Liang, D. Huang, X. Liang et al., Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Lett. 367(1), 1\u201311 (2015)","journal-title":"Cancer Lett."},{"key":"1196_CR23","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.2147\/JHC.S525454","volume":"12","author":"C Wu","year":"2025","unstructured":"C. Wu, Z. Fu, L. Pan, J. Li, Y. Zhou, R. Sun, Y. Gou, Y. Zhao, Z. Wang, Y. Qiu et al., Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Donafenib and Camrelizumab in the Treatment of Patients with Unresectable Hepatocellular Carcinoma: A Retrospective, Single-Arm Study. J. hepatocellular carcinoma. 12, 1353\u20131367 (2025)","journal-title":"J. hepatocellular carcinoma"},{"key":"1196_CR24","doi-asserted-by":"crossref","unstructured":"H. Li, T. Si, R. Li, X. Xie, Y. Liu, L. Fu, Y. Bai, J. Yao, X. Zhang, M. Yang et al., Hepatic arterial infusion chemotherapy with serplulimab and the bevacizumab biosimilar HLX04 for advanced hepatocellular carcinoma: a prospective, observational phase II clinical trial. Cancers. 17(19), (2025)","DOI":"10.3390\/cancers17193235"},{"issue":"3","key":"1196_CR25","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO Clinical","year":"2024","unstructured":"EASL-EASD-EASO Clinical, Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol. 81(3), 492\u2013542 (2024)","journal-title":"J. Hepatol."},{"issue":"2","key":"1196_CR26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ccell.2024.01.007","volume":"42","author":"X Yang","year":"2024","unstructured":"X. Yang, C. Yang, S. Zhang, H. Geng, A.X. Zhu, R. Bernards, W. Qin, J. Fan, C. Wang, Q. Gao, Precision treatment in advanced hepatocellular carcinoma. Cancer cell. 42(2), 180\u2013197 (2024)","journal-title":"Cancer cell."},{"issue":"8","key":"1196_CR27","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41417-024-00764-w","volume":"31","author":"F Safri","year":"2024","unstructured":"F. Safri, R. Nguyen, S. Zerehpooshnesfchi, J. George, L. Qiao, Heterogeneity of hepatocellular carcinoma: from mechanisms to clinical implications. Cancer Gene Ther. 31(8), 1105\u20131112 (2024)","journal-title":"Cancer Gene Ther."},{"issue":"10360","key":"1196_CR28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"A. Vogel, T. Meyer, G. Sapisochin, R. Salem, A. Saborowski, Hepatocellular carcinoma. Lancet (London England). 400(10360), 1345\u20131362 (2022)","journal-title":"Lancet (London England)"},{"issue":"2","key":"1196_CR29","doi-asserted-by":"publisher","first-page":"e230118","DOI":"10.1148\/ryai.230118","volume":"6","author":"O Prior","year":"2024","unstructured":"O. Prior, C. Macarro, V. Navarro, C. Monreal, M. Ligero, A. Garcia-Ruiz, G. Serna, S. Simonetti, I. Bra\u00f1a, M. Vieito et al., Identification of Precise 3D CT Radiomics for Habitat Computation by Machine Learning in Cancer. Radiol. Artif. Intell. 6(2), e230118 (2024)","journal-title":"Radiol. Artif. Intell."},{"key":"1196_CR30","doi-asserted-by":"publisher","first-page":"103186","DOI":"10.1016\/j.eclinm.2025.103186","volume":"82","author":"Y Gao","year":"2025","unstructured":"Y. Gao, Z. Li, X. Zhai, G. Zhang, L. Zhang, T. Huang, L. Han, J. Wang, R. Yan, Y. Li et al., MRI-based habitat radiomics combined with vision transformer for identifying vulnerable intracranial atherosclerotic plaques and predicting stroke events: a multicenter, retrospective study. EClinicalMedicine. 82, 103186 (2025)","journal-title":"EClinicalMedicine"},{"issue":"1","key":"1196_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12967-024-06057-y","volume":"23","author":"Y Wu","year":"2025","unstructured":"Y. Wu, W. Zhang, X. Liang, P. Zhang, M. Zhang, Y. Jiang, Y. Cui, Y. Chen, W. Zhou, Q. Liang et al., Habitat radiomics analysis for progression free survival and immune-related adverse reaction prediction in non-small cell lung cancer treated by immunotherapy. J. translational Med. 23(1), 393 (2025)","journal-title":"J. translational Med."},{"issue":"5","key":"1196_CR32","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1007\/s00330-023-10339-2","volume":"34","author":"Y Zhang","year":"2024","unstructured":"Y. Zhang, J. Chen, C. Yang, Y. Dai, M. Zeng, Preoperative prediction of microvascular invasion in hepatocellular carcinoma using diffusion-weighted imaging-based habitat imaging. Eur. Radiol. 34(5), 3215\u20133225 (2024)","journal-title":"Eur. Radiol."},{"issue":"6","key":"1196_CR33","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/j.acra.2023.11.024","volume":"31","author":"HF Liu","year":"2024","unstructured":"H.F. Liu, M. Wang, Y.J. Lu, Q. Wang, Y. Lu, F. Xing, W. Xing, CEMRI-Based Quantification of Intratumoral Heterogeneity for Predicting Aggressive Characteristics of Hepatocellular Carcinoma Using Habitat Analysis: Comparison and Combination of Deep Learning. Acad. Radiol. 31(6), 2346\u20132355 (2024)","journal-title":"Acad. Radiol."},{"issue":"2","key":"1196_CR34","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","volume":"72","author":"JM Llovet","year":"2020","unstructured":"J.M. Llovet, R. Lencioni, mRECIST for HCC: Performance and novel refinements. J. Hepatol. 72(2), 288\u2013306 (2020)","journal-title":"J. Hepatol."},{"issue":"1","key":"1196_CR35","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"R. Lencioni, J.M. Llovet, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 30(1), 52\u201360 (2010)","journal-title":"Semin. Liver Dis."},{"issue":"4","key":"1196_CR36","doi-asserted-by":"publisher","first-page":"e222729","DOI":"10.1148\/radiol.222729","volume":"307","author":"TY Xia","year":"2023","unstructured":"T.Y. Xia, Z.H. Zhou, X.P. Meng, J.H. Zha, Q. Yu, W.L. Wang, Y. Song, Y.C. Wang, T.Y. Tang, J. Xu et al., Predicting Microvascular Invasion in Hepatocellular Carcinoma Using CT-based Radiomics Model. Radiology. 307(4), e222729 (2023)","journal-title":"Radiology"},{"issue":"1","key":"1196_CR37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12967-024-04904-6","volume":"22","author":"J Peng","year":"2024","unstructured":"J. Peng, D. Zou, X. Zhang, H. Ma, L. Han, B. Yao, A novel sub-regional radiomics model to predict immunotherapy response in non-small cell lung carcinoma. J. translational Med. 22(1), 87 (2024)","journal-title":"J. translational Med."},{"issue":"3","key":"1196_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2967\/jnumed.119.230037","volume":"61","author":"J Wu","year":"2020","unstructured":"J. Wu, M.F. Gensheimer, N. Zhang, M. Guo, R. Liang, C. Zhang, N. Fischbein, E.L. Pollom, B. Beadle, Q.-T. Le et al., Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer. J. Nucl. Med. 61(3), 327 (2020)","journal-title":"J. Nucl. Med."},{"issue":"1","key":"1196_CR39","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1038\/s41467-024-47512-0","volume":"15","author":"SJ Sujit","year":"2024","unstructured":"S.J. Sujit, M. Aminu, T.V. Karpinets, P. Chen, M.B. Saad, M. Salehjahromi, J.D. Boom, M. Qayati, J.M. George, H. Allen et al., Enhancing NSCLC recurrence prediction with PET\/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights. Nat. Commun. 15(1), 3152 (2024)","journal-title":"Nat. Commun."},{"issue":"3","key":"1196_CR40","first-page":"709","volume":"48","author":"M Wu","year":"2025","unstructured":"M. Wu, Z. Que, S. Lai, G. Li, J. Long, Y. He, S. Wang, H. Wu, N. You, X. Lan et al., Predicting the early therapeutic response to hepatic artery infusion chemotherapy in patients with unresectable HCC using a contrast-enhanced computed tomography-based habitat radiomics model: a multi-center retrospective study. Cell. Oncol. (Dordrecht Netherlands). 48(3), 709\u2013723 (2025)","journal-title":"Cell. Oncol. (Dordrecht Netherlands)"},{"issue":"1","key":"1196_CR41","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1148\/radiol.2018172462","volume":"288","author":"J Wu","year":"2018","unstructured":"J. Wu, G. Cao, X. Sun, J. Lee, D.L. Rubin, S. Napel, A.W. Kurian, B.L. Daniel, R. Li, Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. Radiology. 288(1), 26\u201335 (2018)","journal-title":"Radiology"},{"key":"1196_CR42","doi-asserted-by":"crossref","unstructured":"K. Matsuda, A. Ueno, J. Tsuzaki, Y. Kurebayashi, Y. Masugi, K. Yamazaki, M. Tamura, Y. Abe, Y. Hasegawa, M. Kitago et al., Vessels encapsulating tumor clusters contribute to the intratumor heterogeneity of HCC on Gd-EOB-DTPA-enhanced MRI. Hepatol. Commun. 9(1), (2025)","DOI":"10.1097\/HC9.0000000000000593"},{"issue":"10","key":"1196_CR43","doi-asserted-by":"publisher","first-page":"110381","DOI":"10.1016\/j.ejso.2025.110381","volume":"51","author":"T Taniai","year":"2025","unstructured":"T. Taniai, K. Haruki, J.P. V\u00e4yrynen, K. Gomisawa, S. Sato, K. Furukawa, M. Tsunematsu, M. Yanagaki, Y. Shirai, T. Ikegami, Immunological and prognostic significance of vessels encapsulating tumor clusters (VETC) in hepatocellular carcinoma. Eur. J. Surg. oncology: J. Eur. Soc. Surg. Oncol. Br. Association Surg. Oncol. 51(10), 110381 (2025)","journal-title":"Eur. J. Surg. oncology: J. Eur. Soc. Surg. Oncol. Br. Association Surg. Oncol."},{"key":"1196_CR44","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.2147\/JHC.S555248","volume":"12","author":"J Liu","year":"2025","unstructured":"J. Liu, T. Yuan, X. Lv, G. Tan, L. Xue, Z. Huang, Impact of Cytokeratin 19 Expression on the Outcomes of Unresectable Hepatocellular Carcinoma Treated with Targeted Therapy and Immunotherapy: A Propensity Score Matched Analysis. J. hepatocellular carcinoma. 12, 2295\u20132305 (2025)","journal-title":"J. hepatocellular carcinoma"},{"issue":"1","key":"1196_CR45","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1186\/s40001-024-02073-2","volume":"29","author":"AR Devan","year":"2024","unstructured":"A.R. Devan, B. Nair, G.K. Pradeep, R. Alexander, B.S. Vinod, L.R. Nath, D. Calina, J. Sharifi-Rad, The role of glypican-3 in hepatocellular carcinoma: Insights into diagnosis and therapeutic potential. Eur. J. Med. Res. 29(1), 490 (2024)","journal-title":"Eur. J. Med. Res."},{"issue":"3","key":"1196_CR46","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s10637-025-01530-x","volume":"43","author":"X Zhou","year":"2025","unstructured":"X. Zhou, Y. Liu, X. Liu, X. Song, S. Li, P. Chen, X. Jiang, Y. Li, Novel GPC3 N-terminal bispecific antibody exhibits dual anti-tumor effect against tumor cells. Investig. New Drugs. 43(3), 588\u2013601 (2025)","journal-title":"Investig. New Drugs"},{"issue":"3","key":"1196_CR47","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1148\/radiol.2017170845","volume":"287","author":"J Juan-Albarrac\u00edn","year":"2018","unstructured":"J. Juan-Albarrac\u00edn, E. Fuster-Garcia, A. P\u00e9rez-Girb\u00e9s, F. Aparici-Robles, \u00c1. Alberich-Bayarri, A. Revert-Ventura, L. Mart\u00ed-Bonmat\u00ed, J.M. Garc\u00eda-G\u00f3mez, Glioblastoma: Vascular Habitats Detected at Preoperative Dynamic Susceptibility-weighted Contrast-enhanced Perfusion MR Imaging Predict Survival. Radiology. 287(3), 944\u2013954 (2018)","journal-title":"Radiology"}],"container-title":["Cellular Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01196-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13402-026-01196-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13402-026-01196-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T21:02:06Z","timestamp":1774299726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13402-026-01196-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1007\/s13402-026-01196-4","relation":{},"ISSN":["2211-3436"],"issn-type":[{"value":"2211-3436","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"assertion":[{"value":"20 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Following the Declaration of Helsinki, the study received ethical approval from the Ethics Committee of Daping Hospital of Army Medical University (Approval No. 2025(313)), the Ethics Committee of the First Affiliated Hospital of Chongqing Medical University, and the Ethics Committee of the Second Affiliated Hospital of Army Medical University. Informed consent was obtained in advance from all patients participating in the study, permitting the use of their medical records for this research and the publication of the survey results in academic journals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}